Compare Nucor Corporation (NUE) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Nucor Corporation trades at $257.14 (market cap $57.58B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Nucor Corporation is far larger — about 7.7× Spyre Therapeutics Inc. Common Stock's market cap, and Nucor Corporation pays a 0.88% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NUE | SYRE | |
|---|---|---|
Market Cap | $57.58B | $7.52B |
Volume | 874,073 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $108.92 |
52-Week Low | $131.78 | $22.18 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $61.99B | $6.52B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $257.11, up 2.1% today, showing strong momentum with a 50% gain over six months. The stock is in a bullish technical trend, supported by recent earnings beats in Q1 and Q2 2026. Fundamentals reflect solid profitability with a 7.99% net margin and 13.52% ROE, though revenue has moderated from 2022 peaks. The company maintains a strong balance sheet with a debt-to-asset ratio of 20.23% and recently declared its 214th consecutive dividend.
Outlook remains positive with analyst consensus at 'Buy' and a $266.88 price target, though near-term risks include competitive pressures from new steel capacity and volatility in steel prices. Earnings growth and operational efficiency are key catalysts, but investors should monitor Q3 2026 results against expectations of $5.80 EPS.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
